BioSpace News Archive

Five New Directors to Join the Board, James Dallas to Become Independent Chairman in 2022 and Lead Independent Director Immediately.

Braxia Scientific Corp. has reached a milestone as the first Health Canada-approved multiple-dose psilocybin clinical trial which commenced with first patients dosed in November 2021.

Veeva Systems (NYSE: VEEV) today announced that PharmaEssentia has adopted Veeva Data Cloud to support the launch of BESREMi.

Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO ® for the Treatment of Advanced Primary Hyperoxaluria Type 1.

OnKure, Inc. today announced positive topline results from the first-in-human Phase 1 trial of OKI-179, the Company’s oral Class 1 histone deacetylase (HDAC) inhibitor.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS).

Alterity Therapeutics today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity’s Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogens ARESdb contents has grown by more than 40% in a year.

Vera Therapeutics, Inc. today announced the appointment of Kimball Hall to its board of directors.

Centessa Pharmaceuticals plc together with subsidiary Palladio Biosciences, Inc. today announced the initiation of active recruitment of the global ACTION Study, a pivotal Phase 3 clinical trial evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD).